“Building out capabilities that focus on life sciences regulatory advisory and disputes work will be a game-changer for us in Amsterdam,” Wouter Seinen, Amsterdam office head, said in a statement.

He noted that the relocation of the European Medicines Agency to Amsterdam from London in 2019, as part of the post-Brexit transition, would “enable us to tap into opportunities” as clients “increasingly seek on-the-ground capabilities” in the Dutch capital.